Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 5,450 shares at $7.02 ($38K) on 2014-08-13, disclosed to the SEC on 2014-08-15.
Scheduled sale ($38k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.02 | 2,250 | $16K | 41.3% |
| 2 | $7.04 | 1,750 | $12K | 32.2% |
| 3 | $6.98 | 1,450 | $10K | 26.5% |
| Total | $7.02 avg | 5,450 | $38K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |